Infliximab
In pharmacology, infliximab (Remicade®) is a chimeric monoclonal antibody that reduces production of TNF-&alpha (tumour necrosis factor alpha) which has been shown to be part of the autoimmune component in Crohn's disease and rheumatoid arthritis.
Pharmacology
It is made up of part-human part mouse protein, and is administered by intravenous infusion (usually on an outpatient basis). Before infliximab is administered a test for tuberculosis must be performed, as infliximab has been shown to increase the risk of reactivation of latent tuberculosis. Other potential side effects include skin rash, fever, tiredness and difficulty breathing.